Ten Questions Every Clinic Owner Should Answer Before Starting a Retatrutide Program

Before you enroll your first retatrutide research subject, there are ten questions you need to be able to answer. These questions cover the legal, clinical, operational, and financial dimensions of a compliant research program. If you cannot answer all ten, you are not ready to start — and starting before you are ready creates the kind of compliance exposure that can undermine everything you are building.

This is the threshold question. Without an IRB-approved protocol, you do not have authorization to administer retatrutide to human subjects. The protocol must be approved before the first dose is administered — not in process, not pending, approved.

An IRB approval is not a legal opinion. Healthcare counsel review is separate from IRB approval and covers the legal dimensions of the program — state medical practice law, the federal research regulations, the liability structure, and the contractual arrangements with your supplier. Both are required.

You need a supplier who can provide independent third-party COAs covering identity, purity, potency, sterility, and endotoxin testing for every lot. If your supplier cannot provide this documentation, you do not have a compliant supply chain.

Every staff member who touches the research program — physicians, nurses, medical assistants, front desk staff who interact with research subjects — needs to have completed CITI Program training in human subjects research. Document the completion dates and keep the certificates.

The consent document must be the version approved by your IRB. It must be used with every research subject before the first dose. You need a process for conducting the consent discussion, documenting that it occurred, and storing the signed consent forms.

You need a mechanism for patients to report adverse events, a process for documenting them, and a clear protocol for escalating serious adverse events to the IRB within the required timeframe. This system needs to be in place before you enroll the first patient.

Retatrutide requires refrigerated storage at a specified temperature range. You need a dedicated refrigerator with a calibrated temperature monitoring system, a process for documenting storage temperatures, and a protocol for handling temperature excursions.

What will you charge patients? What are your compound costs? What are your IRB fees, healthcare counsel fees, and ongoing compliance costs? What is your break-even enrollment? A program that is not financially sustainable will not be maintained compliantly.

You need defined inclusion and exclusion criteria, a screening process for evaluating prospective research subjects, and a documentation process for recording the screening decision. Enrolling patients who do not meet the inclusion criteria is a protocol deviation — and potentially a patient safety issue.

IRBs can conduct audits of approved research programs. An audit means a reviewer will examine your research records — consent forms, adverse event logs, deviation logs, monitoring visit records, supply chain documentation, staff training records. If you are not prepared to have those records reviewed, you are not ready to run a research program.

If you can answer yes to all ten questions, you are ready to enroll your first research subject. If you cannot, identify the gaps and address them before you start. The compliance infrastructure is not optional — it is the foundation that makes everything else possible.

MedClinic Partners can help with the supply chain and documentation components. For the legal and IRB components, work with healthcare counsel who has experience with investigational compound research programs.